Reviewer's report

**Title:** Quetiapine Augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebo-controlled study

**Version:** 3  **Date:** 23 December 2004

**Reviewer:** Lawrence H Price

**Reviewer's report:**

General
1. The authors have been highly responsive to the initial reviews and the present manuscript is much improved over the original version. The only additional revision needed is to state clearly in the first line of the Conclusions section of the Abstract that quetiapine augmentation was no better than placebo augmentation in this study.

-------------------------------------------------------------------------------
Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)
n/a

-------------------------------------------------------------------------------
Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
n/a

-------------------------------------------------------------------------------
Discretionary Revisions (which the author can choose to ignore)
n/a

**What next?:** Accept after minor essential revisions

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No

**Declaration of competing interests:**

Yes to Q.1: Received speaker's honorarium form the sponsor (AstraZeneca).